BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 33043814)

  • 1. Expression of STAT1 is positively correlated with PD-L1 in human ovarian cancer.
    Liu F; Liu J; Zhang J; Shi J; Gui L; Xu G
    Cancer Biol Ther; 2020 Oct; 21(10):963-971. PubMed ID: 33043814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Expression and significance of PD-1 and PD-L1 in the specimens of epithelial ovarian cancer].
    Ju C; Gao JC; Zhang PX; Zhang KN; Yang S; Kang TJ; Zhao HZ; Qi WJ; Zhang QP; Kong FD; Guan HW; Shi H
    Zhonghua Fu Chan Ke Za Zhi; 2020 Aug; 55(8):529-534. PubMed ID: 32854477
    [No Abstract]   [Full Text] [Related]  

  • 3. IFNγ-induced PD-L1 expression in ovarian cancer cells is regulated by JAK1, STAT1 and IRF1 signaling.
    Padmanabhan S; Gaire B; Zou Y; Uddin MM; Vancurova I
    Cell Signal; 2022 Sep; 97():110400. PubMed ID: 35820543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancer.
    Drakes ML; Mehrotra S; Aldulescu M; Potkul RK; Liu Y; Grisoli A; Joyce C; O'Brien TE; Stack MS; Stiff PJ
    J Ovarian Res; 2018 May; 11(1):43. PubMed ID: 29843813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL-27 induces the expression of IDO and PD-L1 in human cancer cells.
    Carbotti G; Barisione G; Airoldi I; Mezzanzanica D; Bagnoli M; Ferrero S; Petretto A; Fabbi M; Ferrini S
    Oncotarget; 2015 Dec; 6(41):43267-80. PubMed ID: 26657115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long non-coding RNA HOTTIP enhances IL-6 expression to potentiate immune escape of ovarian cancer cells by upregulating the expression of PD-L1 in neutrophils.
    Shang A; Wang W; Gu C; Chen C; Zeng B; Yang Y; Ji P; Sun J; Wu J; Lu W; Sun Z; Li D
    J Exp Clin Cancer Res; 2019 Sep; 38(1):411. PubMed ID: 31533774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intratumoral Delivery of an Adenoviral Vector Carrying the
    Nakagawa S; Serada S; Kakubari R; Hiramatsu K; Sugase T; Matsuzaki S; Matsuzaki S; Ueda Y; Yoshino K; Ohkawara T; Fujimoto M; Kishimoto T; Kimura T; Naka T
    Mol Cancer Ther; 2018 Sep; 17(9):1941-1950. PubMed ID: 29891489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Programmed Death Ligand 1 (PD-L1) Expression in Epithelial Ovarian Cancer: A Comparison of Type I and Type II Tumors.
    Nhokaew W; Kleebkaow P; Chaisuriya N; Kietpeerakool C
    Asian Pac J Cancer Prev; 2019 Apr; 20(4):1161-1169. PubMed ID: 31030490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IFN-γ Promotes Epithelial-Mesenchymal Transition and the Expression of PD-L1 in Pancreatic Cancer.
    Imai D; Yoshizumi T; Okano S; Itoh S; Ikegami T; Harada N; Aishima S; Oda Y; Maehara Y
    J Surg Res; 2019 Aug; 240():115-123. PubMed ID: 30927618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. VISTA expression is associated with a favorable prognosis in patients with high-grade serous ovarian cancer.
    Zong L; Zhou Y; Zhang M; Chen J; Xiang Y
    Cancer Immunol Immunother; 2020 Jan; 69(1):33-42. PubMed ID: 31781843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of programmed cell death ligand 1 and immune checkpoint markers in residual tumors after neoadjuvant chemotherapy for advanced high-grade serous ovarian cancer.
    Kim HS; Kim JY; Lee YJ; Kim SH; Lee JY; Nam EJ; Kim S; Kim SW; Kim YT
    Gynecol Oncol; 2018 Dec; 151(3):414-421. PubMed ID: 30314669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer.
    Webb JR; Milne K; Kroeger DR; Nelson BH
    Gynecol Oncol; 2016 May; 141(2):293-302. PubMed ID: 26972336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. JAK-STAT1 Signaling Pathway Is an Early Response to
    Li X; Pan K; Vieth M; Gerhard M; Li W; Mejías-Luque R
    Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35456965
    [No Abstract]   [Full Text] [Related]  

  • 14. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer.
    Strickland KC; Howitt BE; Shukla SA; Rodig S; Ritterhouse LL; Liu JF; Garber JE; Chowdhury D; Wu CJ; D'Andrea AD; Matulonis UA; Konstantinopoulos PA
    Oncotarget; 2016 Mar; 7(12):13587-98. PubMed ID: 26871470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Use of Programmed Cell Death-1 and Its Ligand Expression as Discriminatory and Predictive Markers in Ovarian Cancer.
    Chatterjee J; Dai W; Aziz NHA; Teo PY; Wahba J; Phelps DL; Maine CJ; Whilding LM; Dina R; Trevisan G; Flower KJ; George AJT; Ghaem-Maghami S
    Clin Cancer Res; 2017 Jul; 23(13):3453-3460. PubMed ID: 27986748
    [No Abstract]   [Full Text] [Related]  

  • 16. Propranolol reduces IFN-γ driven PD-L1 immunosuppression and improves anti-tumour immunity in ovarian cancer.
    Falcinelli M; Al-Hity G; Baron S; Mampay M; Allen MC; Samuels M; Jones W; Cilibrasi C; Flaherty RL; Giamas G; Thaker PH; Flint MS
    Brain Behav Immun; 2023 May; 110():1-12. PubMed ID: 36796704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Translational control of tumor immune escape via the eIF4F-STAT1-PD-L1 axis in melanoma.
    Cerezo M; Guemiri R; Druillennec S; Girault I; Malka-Mahieu H; Shen S; Allard D; Martineau S; Welsch C; Agoussi S; Estrada C; Adam J; Libenciuc C; Routier E; Roy S; Désaubry L; Eggermont AM; Sonenberg N; Scoazec JY; Eychène A; Vagner S; Robert C
    Nat Med; 2018 Dec; 24(12):1877-1886. PubMed ID: 30374200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioinformatics Analysis Identifies
    Guo S; Yang Q
    Front Biosci (Landmark Ed); 2024 Jan; 29(1):39. PubMed ID: 38287833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Programmed death ligand-1 over-expression correlates with malignancy and contributes to immune regulation in ovarian cancer.
    Maine CJ; Aziz NH; Chatterjee J; Hayford C; Brewig N; Whilding L; George AJ; Ghaem-Maghami S
    Cancer Immunol Immunother; 2014 Mar; 63(3):215-24. PubMed ID: 24297569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. miR-375 inhibits IFN-γ-induced programmed death 1 ligand 1 surface expression in head and neck squamous cell carcinoma cells by blocking JAK2/STAT1 signaling.
    Wu Q; Zhao Y; Sun Y; Yan X; Wang P
    Oncol Rep; 2018 Mar; 39(3):1461-1468. PubMed ID: 29328389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.